Found 15 results
Author Title [ Type(Desc)] Year
Filters: Author is Bellamy, Abbie R  [Clear All Filters]
Journal Article
L. Lai, Rouphael, N., Xu, Y., Sherman, A. C., Edupuganti, S., Anderson, E. J., Lankford-Turner, P., Wang, D., Keitel, W., McNeal, M. M., Cross, K., Hill, H., Bellamy, A. R., and Mulligan, M. J., Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine., Vaccines (Basel), vol. 8, no. 1, 2020.
R. B. Belshe, Heineman, T. C., Bernstein, D. I., Bellamy, A. R., Ewell, M., van der Most, R., and Deal, C. D., Correlate of immune protection against HSV-1 genital disease in vaccinated women., J Infect Dis, vol. 209, no. 6, pp. 828-36, 2014.
T. P. Blevins, Yu, Y., Belshe, R. B., Bellamy, A. R., and Morrison, L. A., Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays., PLoS One, vol. 14, no. 4, p. e0214467, 2019.
M. Z. Levine, Holiday, C., Liu, F., Jefferson, S., Gillis, E., Bellamy, A. R., Tumpey, T., and Katz, J. M., Cross-Reactive Antibody Responses to Novel H5Nx Influenza Viruses Following Homologous and Heterologous Prime-Boost Vaccination with a Prepandemic Stockpiled A(H5N1) Vaccine in Humans., J Infect Dis, vol. 216, no. suppl_4, pp. S555-S559, 2017.
J. E. Ledgerwood, Bellamy, A. R., Belshe, R., Bernstein, D. I., Edupuganti, S., Patel, S. M., Renehan, P., Zajdowicz, T., Schwartz, R., Koup, R., Bailer, R. T., Yamshchikov, G. V., Enama, M. E., Sarwar, U., Larkin, B., and Graham, B. S., DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial., PLoS One, vol. 10, no. 5, p. e0125914, 2015.
K. V. Houser, Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Paskel, M., Subbarao, K., Anderson, E., Bernstein, D. I., Creech, B., Keyserling, H., Spearman, P., Wright, P. F., Graham, B. S., and Ledgerwood, J. E., DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial., PLoS One, vol. 13, no. 11, p. e0206837, 2018.
L. A. Jackson, Campbell, J. D., Frey, S. E., Edwards, K. M., Keitel, W. A., Kotloff, K. L., Berry, A. A., Graham, I., Atmar, R. L., C Creech, B., Thomsen, I. P., Patel, S. M., Gutierrez, A. F., Anderson, E. L., Sahly, H. M. El, Hill, H., Noah, D. L., and Bellamy, A. R., Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial., JAMA, vol. 314, no. 3, pp. 237-46, 2015.
D. I. Bernstein, Bellamy, A. R., Hook, E. W., Levin, M. J., Wald, A., Ewell, M. G., Wolff, P. A., Deal, C. D., Heineman, T. C., Dubin, G., and Belshe, R. B., Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women., Clin Infect Dis, vol. 56, no. 3, pp. 344-51, 2013.
J. M. Schulte, Bellamy, A. R., Hook, E. W., Bernstein, D. I., Levin, M. J., Leone, P. A., Sokol-Anderson, M. L., Ewell, M. G., Wolff, P. A., Heineman, T. C., and Belshe, R. B., HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women)., South Med J, vol. 107, no. 2, pp. 79-84, 2014.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
W. A. Keitel, Jackson, L. A., Edupuganti, S., Winokur, P. L., Mulligan, M. J., Thornburg, N. J., Patel, S. M., Rouphael, N. G., Lai, L., Bangaru, S., McNeal, M. M., Bellamy, A. R., and Hill, H. R., Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old., J Infect Dis, vol. 212, no. 4, pp. 552-61, 2015.
C. Carter, Houser, K. V., Yamshchikov, G. V., Bellamy, A. R., May, J., Enama, M. E., Sarwar, U., Larkin, B., Bailer, R. T., Koup, R., Chen, G. L., Patel, S. M., Winokur, P., Belshe, R., Dekker, C. L., Graham, B. S., and Ledgerwood, J. E., Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial., PLoS One, vol. 14, no. 9, p. e0222178, 2019.
F. M. Munoz, Anderson, E. J., Bernstein, D. I., Harrison, C. J., Pahud, B., Anderson, E., C Creech, B., Berry, A. A., Kotloff, K. L., Walter, E. B., Atmar, R. L., Bellamy, A. R., Chang, S., and Keitel, W. A., Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents., Vaccine, vol. 37, no. 36, pp. 5161-5170, 2019.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial., JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
M. D. Tapia, Sow, S. O., Lyke, K. E., Haidara, F. Cheick, Diallo, F., Doumbia, M., Traore, A., Coulibaly, F., Kodio, M., Onwuchekwa, U., Sztein, M. B., Wahid, R., Campbell, J. D., Kieny, M. - P., Moorthy, V., Imoukhuede, E. B., Rampling, T., Roman, F., De Ryck, I., Bellamy, A. R., Dally, L., Mbaya, O. Tshiani, Ploquin, A., Zhou, Y., Stanley, D. A., Bailer, R., Koup, R. A., Roederer, M., Ledgerwood, J., Hill, A. V. S., W Ballou, R., Sullivan, N., Graham, B., and Levine, M. M., Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-bli, Lancet Infect Dis, vol. 16, no. 1, pp. 31-42, 2016.